Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.nefroe.2025.02.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
What the clinician should know when ordering a mast cell tryptase test: A review article for the North American practicing clinician.
Ann Allergy Asthma Immunol
March 2025
University Hospital of Reims, Immunology Laboratory, Biology and Pathology Department, Reims, France; University of Reims Champagne-Ardenne, INSERM UMR 1250, Reims, France. Electronic address:
Tryptase is currently the most specific mast cell biomarker available in clinical laboratories. Tryptase levels in peripheral blood contribute to the diagnostic, prognostic and therapeutic evaluation of three clinical categories: (1) immediate hypersensitivity reactions including the life-threatening systemic form known as anaphylaxis, (2) clonal mast cell diseases and other myeloid malignancies, including as a biomarker for efficacy of chemotherapeutic agents targeting mast cell survival, and (3) hereditary α-tryptasemia (HαT), a genetic trait found in 4 - 8% of general population associated to increased risk of severe immediate hypersensitivity reactions. Rapidly evolving pathophysiology knowledge and management guidelines impact tryptase use in clinical practice, explaining the need for frequent updates.
View Article and Find Full Text PDFTransmission of Severe Fever with Thrombocytopenia Syndrome (SFTS) to humans: A systematic review of individual participant data and meta-analysis.
J Infect Public Health
January 2025
Graduate School of Urban Public Health, University of Seoul, Seoul, Republic of Korea; Department of Urban Big Data Convergence, University of Seoul, Seoul, Republic of Korea. Electronic address:
Severe Fever with Thrombocytopenia Syndrome (SFTS) is a life-threatening emerging infectious disease caused by the SFTS virus. The aim of this systematic review and meta-analysis was to gain new insights into the routes of transmission to humans and assess whether tick bites are the dominant mechanism, as previously reported in the medical literature. Original articles were searched through Embase, Medline, and Global Health from 2009 to 2022.
View Article and Find Full Text PDFLiterature review of occurrence, effectiveness, safety, and hospitalization burden of blood transfusion in the management of warm autoimmune hemolytic anemia.
Hematology
December 2025
Department of Medicine, University of Washington, Seattle, WA, United States.
Introduction: Cases of warm autoimmune hemolytic anemia (wAIHA) often present with life-threatening levels of hemoglobin requiring red blood cell (RBC) transfusion support.
Aim: This literature review assessed the occurrence, safety, effectiveness, and hospitalization burden of RBC transfusions in the management of patients with wAIHA.
Methods: Electronic databases (Embase, MEDLINE) were searched from inception to December 2021 along with additional searches conducted up to March 2024.
Allogeneic stem cell transplantation for MDS-clinical issues, choosing preparative regimens and outcome.
Leuk Lymphoma
March 2025
Department for Hematology, Cellular Therapy, Hemostaseology and Infectious Diseases, University of Leipzig Medical Center, Leipzig, Germany.
Despite the vast heterogeneity of myelodysplastic neoplasm (MDS), treatment options are limited and an allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative approach. While, subsequently, allo-HSCT is the treatment of choice in fit high-risk MDS patients younger than 70 years, it should only be considered in young and fit low-risk MDS patients who suffer from severe and life threatening cytopenias, and fail all available conservative treatment options. With the increasing use of mismatched or haploidentical donors, the majority of MDS patients will have a suitable donor available, however, matched donors should still be preferred if rapidly available.
View Article and Find Full Text PDFPrognostic significance of asymmetric dimethyl arginine level in pediatric patients with COVID-19 infection and MIS-C.
Eur J Pediatr
March 2025
Departments of Pediatric Infectious Diseases, Faculty of Medicine Hospital, Necmettin Erbakan University, Konya, Turkey.
Unlabelled: Coronavirus disease 2019 (COVID-19) and COVID-19-related multisystem inflammatory syndrome in children (MIS-C) is known to be a life-threatening health problem worldwide. The study investigates the potential relationship between asymmetric dimethylarginine (ADMA) levels and disease severity in such conditions. We conducted an observational, prospective study between July 2021 and January 2022.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!